NeuroVision’s $10M in Financing to Support Potential Approach to Detecting Alzheimer’s Using Retinal Imaging

NeuroVision’s $10M in Financing to Support Potential Approach to Detecting Alzheimer’s Using Retinal Imaging
NeuroVision Imaging has raised $10 million in new funding through a Series B financing round, led by a $5 million investment from Wildcat Capital Management. The funds will support NeuroVision's research on retinal imaging technology, a potential new approach to amyloid detection in Alzheimer's disease (AD). A particular hallmark of Alzheimer's is the buildup of amyloid beta plaque in the brain. Today, physicians use positron emission topography (PET scans) and cerebrospinal fluid analysis to detect amyloid for clinical trials and to diagnose Alzheimer's disease. However, these scans are invasive, difficult, and expens
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *